AstraZeneca PLC filed a Form 6-K on 16 November 2026 disclosing that the European Commission has approved Klygefa (gefurulimab), developed by Alexion, AstraZeneca Rare Disease, as an add-on therapy for generalised myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive.

Key Highlights

  • EU approval granted: The European Commission approved Klygefa (gefurulimab) for adults with generalised myasthenia gravis (gMG) who are AChR antibody positive, as an add-on to standard therapy.
  • First-of-its-kind designation: According to the filing, Klygefa is "the first and only dual-binding nanobody C5 inhibitor" approved in the EU, administered once weekly via subcutaneous autoinjector.
  • PREVAIL Phase III trial results: The pivotal trial met its primary endpoint, showing a treatment difference in MG-ADL total score at week 26 of -1.6 (95% CI: -2.4, -0.8), with p<0.0001 versus placebo.
  • Early and sustained benefit: The filing states a clinically meaningful improvement was observed as early as week one and was sustained through week 26.
  • Trial size: The PREVAIL study enrolled 260 patients from 20 countries across North America, Europe, Asia, and the Pacific region.
  • Estimated patient population: The filing cites an estimated 82,500 people diagnosed with gMG in five European countries (Germany, France, UK, Italy, and Spain), with approximately 66,000 being AChR-positive.
  • Existing approvals: Klygefa is already approved in the US, Japan, and other countries for certain adults with gMG, with regulatory submissions under review in China and additional countries.

AstraZeneca's Alexion Unit Secures European Commission Clearance for Klygefa in Rare Neuromuscular Disease

According to the Form 6-K filed by AstraZeneca PLC (LSE/STO/NYSE:AZN) for the month of November 2026, the European Commission granted approval for Klygefa (gefurulimab) based on a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency. The approval covers use as an add-on to standard therapy for gMG in adults who test positive for anti-acetylcholine receptor antibodies. The filing describes gMG as "a rare autoimmune disorder characterised by reduced muscle function and severe muscle weakness."

The approval was supported by results from the PREVAIL (ALXN1720-MG-301) Phase III study, which the filing describes as "a global, Phase III, randomised, double-blind, placebo-controlled, parallel, multicentre study." Patients were randomised 1:1 to receive Klygefa or placebo over a 26-week randomised controlled treatment period, with a single weight-based loading dose on Day 1 followed by once-weekly maintenance dosing beginning on Day 8. The filing reports that the primary endpoint, change from baseline in MG-ADL total score at week 26, showed a treatment difference of -1.6 (95% CI: -2.4, -0.8), p<0.0001. The filing adds that PREVAIL trial data were presented at the MGFA Scientific Session during the AANEM 2025 Annual Meeting and published in JAMA Neurology.

The filing states that Klygefa "was generally well-tolerated, and the safety profile was consistent with previous trials of C5 inhibitors eculizumab and ravulizumab in gMG." Klygefa works, according to the filing, by binding to the C5 protein in the terminal complement cascade, with concurrent binding to serum albumin providing an extended half-life that enables once-weekly dosing. Patients who completed the randomised controlled treatment period were eligible to enter an open-label extension period, which the filing describes as ongoing.

What Was Disclosed

AstraZeneca's Form 6-K disclosed the European Commission's approval of Klygefa (gefurulimab) for adults with AChR antibody-positive gMG, based on PREVAIL Phase III trial results, with the drug described as the first and only dual-binding nanobody C5 inhibitor approved in the EU.